Truist analyst Robyn Karnauskas lowered the firm’s price target on Coherus Biosciences (CHRS) to $22 from $24 but keeps a Buy rating on the shares. The company’s acquisition of Surface Oncology (SURF) makes sense considering the combination potential of Tori with Surface’s novel agents, the analyst tells investors in a research note. The firm adds that Coherus Biosciences is not getting credit for the cost savings due to R&D synergies.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on CHRS:
- Surface Oncology downgraded to Neutral from Outperform at Baird
- Surface Oncology downgraded to Neutral from Buy at H.C. Wainwright
- Coherus Biosciences reaffirms 2023 net revenue view in excess of $275M
- Surface Oncology implements 50% workforce reduction
- Coherus Biosciences to acquire Surface Oncology in stock for stock transaction